About this trial
The goal of this observational cross-sectional study is to determine the salivary levels of E-cadherin, Calprotectin, and Matrix Metalloproteinase-9 (MMP-9) in patients with Recurrent Aphthous Stomatitis (RAS) and to compare them with those of healthy controls.
The main questions it aims to answer are:
Are the salivary levels of E-cadherin, Calprotectin, and MMP-9 significantly different in patients with minor RAS compared to healthy controls?
Can these salivary proteins serve as biomarkers involved in the pathogenesis of minor RAS?
Researchers will compare patients with minor RAS and healthy individuals to determine whether differences in salivary E-cadherin, Calprotectin, and MMP-9 levels are associated with the presence of disease.
Participants will:
Provide unstimulated saliva samples using a saliva swab
Undergo clinical evaluation for periodontal status (Community Periodontal Index - CPI) and caries experience (DMFT index)
Collected saliva samples will be stored at -80°C until analysis. The concentrations of the investigated proteins will be measured using ELISA kits, and total protein levels will be determined using a colorimetric protein assay.
The relationships among the salivary concentrations of the investigated proteins, as well as their associations with demographic variables such as age and sex, will be analyzed.
Eligibility criteria
Qualifiers
Participants aged 18 years or older
Clinically diagnosed with minor recurrent aphthous stomatitis (RAS) (defined as having a history of at least three RAS episodes within the past year)
Systemically healthy (i.e., without any diagnosed systemic disease)
No history of tobacco use
Disqualifiers
Use of any pharmacological treatment within the past 3 months
Use of antiseptic mouthwash within the past 3 months
Pregnant or lactating individuals, or those currently using oral contraceptives
History of systemic diseases associated with oral ulcerations such as Crohn's disease, ulcerative colitis, celiac disease, or Behçet's disease
Trial design
Treatments tested in this trial
- ELISA
Treatment groups
Sponsors and collaborators
Selin Yeşiltepe
Lead sponsor
Aydin Adnan Menderes University
Sponsor institution
Aydın Adnan Menderes University Scientific Research Projects Unit
Collaborator
Aydin Adnan Menderes University
Collaborator